PennyPerformers.com: "Penny Stocks that Perform" picks are: CEXI, CGYV, NTRO, OCBM, ZYXI

Nov 06, 2008 (M2 PRESSWIRE via COMTEX) -- ZYXI | Quote | Chart | News | PowerRating -- Pennyperformers.com "Penny Stocks that Perform" picks are: CDEX Inc. (OTCBB: CEXI), China Energy Recovery, Inc. (OTCBB: CGYV), Nitro Petroleum, Inc. (OTCBB: NTRO), OpenCell BioMed Inc. (OTCBB: OCBM), Zynex, Inc. (OTCBB: ZYXI)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com

Nov 06, 2008 -- Following up on recent announcements related to global expansion, CDEX Inc. (OTCBB: CEXI | Quote | Chart | News | PowerRating) announces record ValiMed sales and more than doubling of its hospital client base in FY08, which ended October 31, with eleven ValiMed units sold or leased in the fourth quarter and, in addition, a backlog of orders. Going into FY09 with a backlog and a strong sales pipeline, CDEX projects that in the first six months of FY09 it will sell or lease over 25 new ValiMed units, continuing the trend of year-over-year growth.

The ValiMed Medication Safety and Narcotics Returns System improves patient safety by reducing medication errors, detecting harmful counterfeits, identifying narcotic diversion and training compounding medical personnel. Within seconds, ValiMed analyzes a medication's spectroscopic signature and concentration and returns a quantitative result, requiring no user interpretation (see the Medication Safety section of our web site, www.cdexinc.com).

"We are pleased with the continuing penetration of ValiMed into the U.S. healthcare market and the expansion of that market globally," said Malcolm Philips, CDEX CEO and Chairman. "We ended FY08 strong with an increase in the number of ValiMed units in the field, which not only increases sale and lease revenue, but also should contribute to a growing recurring revenue stream from service fees and the sale of supplies."

"Momentum is building," added Pascal Pouligny, VP and GM of the Medication Safety Division at CDEX. "Leading hospitals have adopted our technology and ValiMed has been cited by key national patient safety associations and organizations. This activity has resulted in an increasing number of requests for information and demonstrations of our system, translating into sales and leases. Indeed, we are benefiting from greater industry awareness about and critical acceptance of our Medication Safety Products."

"Our future plans are exciting," Pouligny continued. "First, we are introducing the next generation of ValiMed systems at the upcoming American Society of Health-System Pharmacists meeting in Orlando, Florida, in December. These new models and applications are flexible and designed to accommodate the varying requirements of our customers worldwide. Secondly, our strong U.S. sales pipeline should result in continued growth of our market share and branding of ValiMed as a standard of medication safety. Third, our international expansion should also continue in FY09 with the addition of new distributor geographies and opportunities related to co-development and marketing initiatives with key partners in Europe to customize our medication signatures offering for the ValiMed Systems."

"In light of our progress, we believe more sales and leases of ValiMed systems will occur in the first two quarters of FY09 than occurred in all of FY08," concluded Pouligny. (For more discussion listen to Mr. Pouligny's briefing in the Investor Section of our website.)

About CDEX

CDEX is a technology development company, currently manufacturing and globally distributing chemical detection products in the medication safety and security markets. The ValiMed(TM) product line provides life-saving validation of high-risk medications and returned narcotics. The ID(2 )(TM) product line is a revolutionary new tool in the global battle against abuse of illegal drugs such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets and applications. To meet its plans, however, CDEX must raise additional funds as set forth from time to time in its SEC filings.

Nov 06, 2008 -- China Energy Recovery, Inc. (OTCBB: CGYV | Quote | Chart | News | PowerRating) ("CER"), a leader in the waste heat energy recovery sector of the alternative energy industry, announced today that it has executed contracts for designing and manufacturing the world's largest straw pulp alkali recovery system in alliance with CMIIC Engineering & Construction Corporation, one of China's largest industrial construction firms. The recovery system is a key part of the Shandong Hai River Basin Pollution Control Project sponsored by the Asian Development Bank. The total project cost is estimated to be RMB95 million (approximately US$13.9 million based on the exchange rate as of date of this press release date), of which RMB79 million (approximately US$11.6 million) represents the estimated cost for the alkali recovery system that CER will design and manufacture leveraging its own technology.

The system is to be built for Shandong Tralin Group ("Tralin"), one of the top paper manufacturers in China. The CER technology will treat the toxic residual black liquor generated from the pulp making process to create cleaner discharge. The system is designed to process 1,200 tons of black liquor per day and expected to enable Tralin to meet the government mandate on minimizing pollutant discharge.

The system is also designed to generate 145 tons of steam per hour. This is equivalent to nearly 12MW of heat energy generation capacity and expected to enable Tralin to reduce the cost of purchasing steam from outside vendors needed to power its paper making facility. Additionally, the system is expected to recover 195 tons of alkali per day, which can be reused in the pulp making process, thus further reducing material costs and bringing multiple benefits to Tralin.

"We expect that the system will be the largest of its kind in the world upon completion and designed and developed entirely based on our own technology. This signifies an important milestone for our further expansion in the market of waste treatment and energy recovery of the paper-making industry both in China and abroad," commented CER Chairman of the Board and CEO, Mr. Qinghuan Wu. "We're pleased to see that both the Asian Development Bank and Shandong Tralin Group have seen the value that CER can bring to them by endorsing our technology and system which we believe can specifically address their problems."

Mr. Wu also commented, "With the addition of this project, we have already secured orders with a total contract value of approximately RMB130 million (US$19 million) for 2009. We have seen a steady flow of new business bookings, which we expect will bring continued substantial growth in 2009. Our dual growth drivers of reducing energy costs while reducing pollutants are continuing to drive our growth. The current global economic slowdown does not appear to affect that."

The numbers presented above are total contract values, which include a 17% value added tax and the retainage amount for product warranty purposes, which is 5% of the total contract values and will be recognized as deferred revenues. The numbers presented represent values based on current exchange rates. Changes in the currency exchange rates would result in a commensurate change in contract value.

What is Waste Heat Energy Recovery?

Industrial facilities release significant amounts of excess heat into the atmosphere in the form of hot exhaust gases or high-pressure steam. Energy recovery is the process of recovering vast amounts of that wasted energy and converting it into usable heat energy or electricity, dramatically lowering energy costs. Energy recovery systems are also capable of capturing harmful pollutants that would otherwise be released into the environment. It is estimated that if energy currently wasted by all the U.S. industrial facilities could be recovered, it could produce power equivalent to 20% of U.S. electricity generation capacity without burning any additional fossil fuel, and could help many industries to meet stringent environmental regulations.

About China Energy Recovery, Inc.

CER is an international leader in energy recovery systems, with a primary focus on the Chinese market. CER's technology captures industrial waste energy to produce low-cost electrical power, enabling industrial manufacturers to reduce their energy costs, shrink their emissions footprint, and generate sellable emissions credits. CER has deployed its systems throughout China and in such international markets as Egypt, Turkey, Korea, Vietnam and Malaysia. CER focuses on numerous industries in which a rapid payback on invested capital is achieved by its customers, including: chemical, petro-chemicals, refining (including Ethanol refining), coke processing, and the manufacture of paper, cement and steel. CER continues to invest in R&D and plans to build China's first state-of-the-art energy recovery system research and fabrication facility to allow it to meet the increased demand for its products and services.

Nov 06, 2008 -- Nitro Petroleum, Inc. (OTCBB: NTRO | Quote | Chart | News | PowerRating) is pleased to report the following Field updates to its shareholders.

Nitro Petroleum, Inc. reports today the completion of the Re Work on the Nancy Hubbard was completed and the Well is now in production. The well was put on line October 30th. 2008. The well is already producing Oil but has to pump out all the Fluids (Frac-water) before increasing the Oil cut. This project is a 4 Well program and has one Water Disposal Well on the property. The next wells to perform a Major re-work on will be the Krouch 1 test and frac the 1st Wilcox payzone. The Walker well will be fraced into the Hunton Limestone formation. These wells are 7000 feet in depth. Nitro will report Oil production shortly on the Nancy Hubbard once we have recovered our frac-water.

Nitro Petroleum, Inc. will keep its shareholders updated on events as they unfold.

About Nitro Petroleum, Inc.

Nitro Petroleum, Inc. ("Nitro") is a natural resource company engaged in the development and re-development of oil and gas fields in the United States. Nitro's business strategy is to identify and develop oil and gas reserves that provide low cost barrier and an appreciation of value.

Nov 06, 2008 -- OpenCell BioMed Inc. (OTCBB: OCBM | Quote | Chart | News | PowerRating) is a medical device designer and manufacturer specializing in innovative designs merging proprietary biomedical materials with human cell biology. The company is developing a unique line of dental implants and related products for sale worldwide. OpenCell BioMed is differentiated by its proprietary paradigm shift surface coating/material TI- FOAM(TM) used as the bone to implant interface enabling dental implant systems greater short and long term stability with a minimally invasive techniques compared to traditional dental implant systems. In 2006, the global dental implant market was valued at over $1,790 million (www.mrg.net). Studies show that 69% of adults ages 35 to 44 have lost at least one permanent tooth to an accident, gum disease, a failed root canal or tooth decay. Furthermore, by age 74, 26% of adults have lost all of their permanent teeth and with the number of Americans over 55 growing by 60% in the next 20 years and their buying power exceeding $2 trillion by 2007. (Business Communications Co., Inc., February 2005)

"We are excited to be entering the multi-billion dollar a year medical device market. We are confident that OpenCell BioMed will be able to capture a significant market share in a sector that is seeing an erosion of market share from previously dominant players. With the aging population and with a doubling in the last decade of healthcare spending OpenCell BioMed and its proprietary products are uniquely positioned for many years of unprecedented growth." (Dr. Mislav Pavelic CEO-OpenCell BioMed Inc.)

About OpenCell BioMed Inc.

OpenCell BioMed is a medical device designer and manufacturer specializing in innovative designs merging proprietary biomedical materials with human cell biology. The company is developing a unique line of dental implants and related products for sale worldwide.

About Dental Implants

Dental implants are designed as permanent replacements for missing teeth. A dental implant is a metal post that is surgically placed into the bone under the gums. The purpose of the placement into the bone is to encourage the integration of the dental implants. The bone actually grows around the dental implant, making the tooth secure. A replacement tooth is attached to the titanium post by means of a final abutment. Did you know that dental implants are frequently the best treatment option for replacing missing teeth? Rather than resting on the gum line like removable dentures, or using adjacent teeth as anchors like fixed bridges, dental implants are long-term replacements.

Nov 06, 2008 -- Zynex, Inc. (OTCBB: ZYXI), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces an increase in its orders of 136% for October of 2008 compared to the same month last year.

Thomas Sandgaard, CEO, said: "We are excited to see our orders continue to increase and post another record month. We also are continuing our discussions with Anthem with the goal of a better result than the previously announced claim. We continue to have a good relationship with Anthem and provide service to patients with Anthem insurance."

Zynex received 3,177 orders for October of 2008; of this number, 264 were orders for devices for which Anthem is currently denying payments. Although the Company is moving to only providing Anthem insureds with alternative and currently reimbursed devices, some orders were still in the pipeline and included in the orders for October 2008. In addition, the Company is seeking to replace some unreimbursed devices placed in October with Anthem patients.

Zynex received 2,643 orders in September of 2008; of these, 624 orders were for devices for which Anthem is currently denying payments and which could have been replaced with alternative devices in Zynex's portfolio. Orders in October of 2007 were 1,452 of which 217 were for devices that Anthem is currently denying payment.

Zynex has not yet finalized its results for the third and fourth quarters of 2008, including the impact of increased orders.

About Zynex, Inc.

Zynex (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.

About PennyPerformers.com

PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.

Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm

CONTACT: PennyPerformers.com e-mail: info@pennyperformers.com WWW: http://www.PennyPerformers.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index